PURPOSE: We evaluated central retinal thickness (CRT) in diabetic macular edema (DME) using two different spectral-domain (SD) optical coherence tomography (OCT) instruments: the Cirrus and Spectralis OCTs. METHODS: CRT was measured in 63 eyes of 32 patients with DME using both instruments on the same day. RESULTS: CRT measurements were significantly greater for the Spectralis than the Cirrus (p < 0.0003, n = 63, paired t test); mean CRT values were 382 ± 136 μm with the Cirrus and 394 ± 139 μm with the Spectralis. In eyes with poor best-corrected visual acuity (BCVA) (<20/40), mean CRT was 378 ± 130 μm with the Cirrus and 395 ± 139 μm with the Spectralis (p < 0.007, n = 29). In eyes with good acuity (equal to or better than 20/40), the mean CRT was 385 ± 142 μm with the Cirrus and 393 ± 140 μm with the Spectralis (p < 0.005, n = 34). CONCLUSIONS: Foveal retinal thickness measurements may vary among SD-OCT devices. The differences between instruments could affect the results of a multicenter study.
PURPOSE: We evaluated central retinal thickness (CRT) in diabetic macular edema (DME) using two different spectral-domain (SD) optical coherence tomography (OCT) instruments: the Cirrus and Spectralis OCTs. METHODS: CRT was measured in 63 eyes of 32 patients with DME using both instruments on the same day. RESULTS: CRT measurements were significantly greater for the Spectralis than the Cirrus (p < 0.0003, n = 63, paired t test); mean CRT values were 382 ± 136 μm with the Cirrus and 394 ± 139 μm with the Spectralis. In eyes with poor best-corrected visual acuity (BCVA) (<20/40), mean CRT was 378 ± 130 μm with the Cirrus and 395 ± 139 μm with the Spectralis (p < 0.007, n = 29). In eyes with good acuity (equal to or better than 20/40), the mean CRT was 385 ± 142 μm with the Cirrus and 393 ± 140 μm with the Spectralis (p < 0.005, n = 34). CONCLUSIONS: Foveal retinal thickness measurements may vary among SD-OCT devices. The differences between instruments could affect the results of a multicenter study.
Authors: Farzin Forooghian; Catherine Cukras; Catherine B Meyerle; Emily Y Chew; Wai T Wong Journal: Invest Ophthalmol Vis Sci Date: 2008-05-30 Impact factor: 4.799
Authors: C A Puliafito; M R Hee; C P Lin; E Reichel; J S Schuman; J S Duker; J A Izatt; E A Swanson; J G Fujimoto Journal: Ophthalmology Date: 1995-02 Impact factor: 12.079
Authors: Magdalena G Krzystolik; Samara F Strauber; Lloyd Paul Aiello; Roy W Beck; Brian B Berger; Neil M Bressler; David J Browning; Robert B Chambers; Ronald P Danis; Matthew D Davis; Adam R Glassman; Victor H Gonzalez; Paul B Greenberg; Jeffrey G Gross; Judy E Kim; Craig Kollman Journal: Ophthalmology Date: 2007-03-13 Impact factor: 12.079
Authors: Ute E K Wolf-Schnurrbusch; Lala Ceklic; Christian K Brinkmann; Milko E Iliev; Manuel Frey; Simon P Rothenbuehler; Volker Enzmann; Sebastian Wolf Journal: Invest Ophthalmol Vis Sci Date: 2009-02-21 Impact factor: 4.799
Authors: David J Browning; Adam R Glassman; Lloyd P Aiello; Neil M Bressler; Susan B Bressler; Ronald P Danis; Matthew D Davis; Frederick L Ferris; Suber S Huang; Peter K Kaiser; Craig Kollman; Srinavas Sadda; Ingrid U Scott; Haijing Qin Journal: Ophthalmology Date: 2008-08 Impact factor: 12.079
Authors: Matthew D Davis; Susan B Bressler; Lloyd Paul Aiello; Neil M Bressler; David J Browning; Christina J Flaxel; Donald S Fong; William J Foster; Adam R Glassman; Mary Elizabeth R Hartnett; Craig Kollman; Helen K Li; Haijing Qin; Ingrid U Scott Journal: Invest Ophthalmol Vis Sci Date: 2008-03-03 Impact factor: 4.799